Recent
price
P/E
ratio
div
yld
26.14%
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.ArriVent BioPharma: ARR-217 Gives Us A Reason To Reconsider Our Strong Sell (Rating Upgrade)
Jensen Huang Is Out. What Happens to Nvidia Stock Now?
11% Dividend Yield: What The Market Misses About My Biggest Position
Baron Small Cap Fund Q3 2026 Top Contributors And Detractors
ARMOUR Residential REIT, Inc. Announces Participation in Citizens Financial Services Conference and Updated November Book Value Estimate
Is America's AI Data Center Boom About to Hit a Brick Wall?
eGain Reports First Quarter Fiscal 2027 Financial Results; Revenue and Earnings Exceed High End of Guidance; AI Customer ARR Grows 11%
Polen 5Perspectives Large Growth Composite Q3 2026 Portfolio Performance And Attribution
Nebius Stock Is Down 30%. Could Its $9 Billion ARR Goal Spark a Rebound?
Baron SMID Cap ETF Q3 2026 Contributors And Detractors
Buy 13 IDEAL 'Safer' October LoPrice/HiDividend Small Cap 'Toy Dogs'
ARMOUR Residential: 3 Key Takeaways for Long-Term Investors
Armour Residential REIT: A Discounted Recovery Play Earns A Cautious Buy
ArriVent BioPharma's ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study
Armour Residential REIT: Sidelined Again As A High-Yield Idea With MBS Volatility
REITs Rebound As Earnings Deliver
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
ARMOUR Residential REIT, Inc. (ARR) Q3 2026 Earnings Call Transcript
ARMOUR Residential REIT Q3 Earnings Call Highlights
Armour Residential REIT (ARR) Q3 Earnings Lag Estimates